Puneet Souda

Sung Ji Nam

Tycho Peterson

Brandon Couillard

David Westenberg

Douglas Schenkel

Mason Carrico

Michael Ryskin

Tejas Savant

Andrew Cooper

Ben...

Bill Bonello

Dan Brennan

Doug Schenkel

Jason Lai

Kyle Boucher

Lu Li

Madison Pasterchick

Matt Sik

Prashant Kota

Rachel Vatnsdal Olson

Ricki Levitus

Subhalaxmi Nambi

Thomas...

William Bonello

- Myriad Genetics, Inc. announced the publication of a new meta-analysis of **six prospective controlled studies** that included **3,532 adults** with major depressive disorder (MDD).  **[899923_ef9bf2d04dd1429f9986f5e343a5bc45_0]** 
- The meta-analysis showed that when GeneSight® Psychotropic test results were available to treating clinicians, there were **significant improvements in response and remission rates** for patients with MDD, compared to treatment as usual (TAU).  **[899923_ef9bf2d04dd1429f9986f5e343a5bc45_0]** 
- Specifically, patients in the GeneSight arm were **41% more likely to achieve remission** and **30% more likely to achieve response** compared to TAU.  **[899923_ef9bf2d04dd1429f9986f5e343a5bc45_0]** 
- This large-scale data analysis provides evidence of the clinical utility of the GeneSight Psychotropic test for patients with MDD who have experienced at least one treatment failure.  **[899923_ef9bf2d04dd1429f9986f5e343a5bc45_1]** 
- Myriad Genetics plans to **submit this data to payers** as part of ongoing efforts to increase patient access to the GeneSight test.  **[899923_ef9bf2d04dd1429f9986f5e343a5bc45_1]**

Myriad Genetics announces new meta-analysis results for GeneSight test

MYRIAD GENETICS (MYGN)